Bioinformatics and applied genomics for identifying targets for drugs and diagnostics

Pathogenesis and host / pathogen interactions

Socioeconomic impact of human African trypanosomiasis and cost-benefit of control

Effect of health systems and policy changes on human African trypanosomiasis control, re-emergence, and epidemics

Factors influencing individual and community participation in control

Epidemiological significance of animal reservoirs for Trypanosoma gambiense

Tsetse genomics for vector control
  

Molecular tools for Aedes transformation; vectorial resistance to dengue; Aedes population genetics and ecology

Host-pathogen interactions in dengue, including pathogenesis, natural history, definition of high risk groups

Dynamics of virus transmission, and population genetics (including modelling)

Social, economic, and biological factors related to (a) promotion and support of community-based interventions and (b) release of transformed Aedes vectors
  

Bioinformatics and applied genomics for identifying targets for drugs, vaccines, and diagnostics

Pathogenesis and host interactions

Understanding mechanisms for drug resistance

Impact of inequity of access to services and health sector reform

Socioeconomic, environmental, and behavioural risk factors for infection and disease, especially in refugee populations in complex emergencies
  

Anopheles genomics and population genetics and genetic manipulation for malaria vector control

Bioinformatics and applied genomics for identifying targets for drugs, vaccines and diagnostics, and elucidating of pathogenesis and risk factors

Impact of health sector reform, globalization and inequality of access to treatment and prevention

Understanding mechanisms of resistance to drugs and insecticides
  

Bioinformatics and applied genomics for identifying targets for drugs, vaccines, and diagnostics

Pathogenesis (host-pathogen interactions) focusing on reproductive health issues and immunological aspects of co-infection

Social economic impact and methodology for burden of disease assessment
  

Bioinformatics and applied genomics for identifying targets for drugs, vaccines, and diagnostics

Impact of health sector reform, globalization, and inequality of access
  

Bioinformatics and applied genomics for identifying targets for drugs and elucidation of pathogenesis and risk factors

Genetic and entomological studies on vectors (e.g. mechanisms of resistance, adaptation to ecological changes)
  

Bioinformatics and applied genomics for identifying targets for diagnostics for infection with Mycobacterium leprae

Pathogenesis of nerve reactions

Social and behavioural constraints for leprosy elimination
  

Bioinformatics and applied genomics for identifying targets for drugs

Progression / reversibility of disease manifestations after treatment, especially in children
  

Bioinformatics and applied genomics for identifying targets for drugs

Understanding ivermectin resistance mechanisms
  

Discovery and development of new drugs and improved formulations

Dipstick format diagnostic test for patent infection with improved specificity

Diagnostics to monitor central nervous system disease stage and determine cure
  

Development of new vaccines, including the application of guidelines for trials of dengue vaccines in endemic populations

Assess technical and use profiles of available diagnostics
  

Discovery and development of new drugs

Development of Leishmania diagnostic tests

Development of vaccine candidates (new adjuvants for first generation vaccines; second generation vaccine)
  

Discovery and development of new drugs, including combinations and drugs for use in pregnancy

Development and development of malaria vaccine candidates

Development of non-invasive approach to diagnostics for use close to the home
  

Discovery and development of new drugs

Evaluate safety and efficacy of existing drugs that are potentially anti-schistosomal

Identification of schistosomiasis vaccine candidates

Assess technical and use profiles of available diagnostics
  

Diagnostic test development; detection of disease, rifampicin resistance, latent infection

Discovery and development of new drugs
  

Discovery and development of new drugs

Clinical research on proposed prognostic markers of disease
  

Rifampicin susceptibility test development

Development of a test for infection with Mycobacterium leprae

Development of tools for early diagnosis and treatment of leprosy reactions
  

Discovery and development of macrofilaricidal drugs or drugs to permanently inhibit microfilariae production

Further development and evaluation of diagnostics for Brugia malayi
  

Discovery and development of macrofilaricidal drugs or drugs to permanently inhibit microfilariae production

Development of diagnostics for surveillance

Development of ivermectin resistance test
  

Clinical / epidemiological significance of Card Agglutination Test for Trypanosomiasis (CATT) or Card Indirect Agglutination Test for Trypanosomiasis Test (CIATT) -positive, but parasite negative cases

Evaluation of short treatment duration for pentamidine, suramin, and melarsoprol

To investigate the existence or melarsoprol resistance
  

Improve existing treatment and prevention methods for new indications in children and pregnant women

Development of methods / tools to improve access to prevention, early treatment and referral of malaria

Development and evaluation of combination therpies for drug resistant malaria
  

Field evaluation of existing diagnostics

Rapid assessment method for prevalence of intestinal schistsosomiasis

Optimization of praziquantel (alone or in combination with artemisinins or oxamniquine)
  

Assessment of the effectiveness and safety of fixed dose combinations (FDC) for use in TB control

Determination of the role of preventive therapy in prevention of TB in HIV-positive individuals in high HIV-prevalence settings
  

Development of methods for control of non-domiciliated vectors

Insecticide effectiveness and the emergence of vector resistance

Evaluation of vector detection tools in low density transmission areas

Evaluation of non-conventional diagnostics
  

Cost-effective delivery strategies for new drugs against visceral leishmaniasis

Development of strategies for use of insecticide treated materials (ITNs)
  

Developing strategies for cost-effective implementation and scaling up of new methods to treat and prevent malaria, focusing on home management of fever, deployment of rectal artesunate and intermittent preventive treatment

Provision of evidence for policy changes on combination treatment and prevention of malaria complications 
  

Improved strategy for control of non-domiciliated triatomines

Development of strategies for control of expansion of infection within the Amazon region

New indicators for control programmes

Identification of determinants of effective implementation for Trypanosoma cruzi-safe blood programmes
  

Development of strategies for integration of multidrug therapy (MDT) into general health services

Modelling the impact of MDT on transmission

Development of evidence-based guidelines for elimination strategies using available drug combinations

Development of improved drug delivery strategies, especially in urban settings

Development of sustainable strategies for management of lymphoedema and genito-urinary complications
 

Development of strategies for sustainable drug delivery post Onchocerciasis Control Programme (OCP) and African Programme for Onchocerciasis Control (APOC)

Feasibility and cost-benefit of onchocerciasis elimination with ivermectin

Development of rapid mapping strategies for Loa loa.